510(k) Summary of Safety and Effectiveness

Applicant Name and Address: Collagen Matrix, Inc.
509 Commerce Street
Franklin Lakes, New Jersey 07417

Contact Person: Peggy Hansen, RAC
Sr. Director, Clinical, Regulatory, and QA
Tel: (201) 405-1477
Fax: (201) 405-1355

Date of Summary: August 24, 2007

Device Common Name: Bone Grafting Material

Device Trade Name: SynOss™ Synthetic Bone Graft Material

Device Classification Name: Bone Grafting Material, Synthetic
872.3930
LYC
Class II

Predicate Device(s): OsteoGuide™ Anorganic Bone Mineral Products
K043034

Description of the Device

SynOss™ Synthetic Bone Graft Material is an osteoconductive calcium phosphate based bone graft material with an apatite structure similar to that of human bone. The product is supplied in granular form, and it is sterile, non-pyrogenic, and for single use only.

Intended Use

SynOss Synthetic Bone Graft Material is intended for use in dental surgery. The products may be used in surgical procedures such as:

- Augmentation or reconstructive treatment of alveolar ridge
- Filling of periodontal defects
- Filling of defects after root resection, apicocectomy, and cystectomy
- Filling of extraction sockets to enhance preservation of the alveolar ridge
- Elevation of maxillary sinus floor
- Filling of periodontal defects in conjunction with products intended for Guided Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR)
- Filling of peri-implant defects in conjunction with products intended for Guided Bone Regeneration
SynOss Synthetic Bone Graft Material and its predicate have the same technological characteristics. In particular, the both SynOss and its predicate are the same with respect to intended use, material structure, material characterization, form, and sizes.

Safety

SynOss Synthetic Bone Graft Material has been evaluated by a number of tests to assess its safety/biocompatibility. The device passed all selected FDA Blue Book Memorandum G95-1 and ISO 10993-1 testing for the biological evaluation of medical devices.

Effectiveness

The characteristics of the SynOss Synthetic Bone Graft Material meet the design requirements for an effective bone grafting material.

Conclusion

The results of the \textit{in vitro} product characterization studies, \textit{in vitro} and \textit{in vivo} biocompatibility studies, show that the SynOss Synthetic Bone Graft Material is safe and substantially equivalent to OsteoGuide Anorganic Bone Mineral Granules.
Ms. Peggy Hansen  
Senior Director, Clinical, Regulatory, and Quality Assurance  
Collagen Matrix, Incorporated  
509 Commerce Street  
Franklin Lakes, New Jersey  07417  

Re: K072397  
Trade/Device Name: SynOss™ Synthetic Bone Graft Material  
Regulation Number: 21 CFR 872.3930  
Regulation Name: Bone Grafting Material  
Regulatory Class: II  
Product Code: LYC  
Dated: August 24, 2007  
Received: August 27, 2007  

Dear Ms. Hansen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Chiu Lin, Ph.D.
Director
Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure
Indications for Use

510(k) Number (if known): 4072397

Device Name: SynOss™ Synthetic Bone Graft Material

Indications for Use:

SynOss Synthetic Bone Graft Material is intended for use in dental surgery. The products may be used in surgical procedures such as:

- Augmentation or reconstructive treatment of alveolar ridge
- Filling of periodontal defects
- Filling of defects after root resection, apicoectomy, and cystectomy
- Filling of extraction sockets to enhance preservation of the alveolar ridge
- Elevation of maxillary sinus floor
- Filling of periodontal defects in conjunction with products intended for Guided Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR)
- Filling of peri-implant defects in conjunction with products intended for Guided Bone Regeneration

Prescription Use X AND/OR Over-The-Counter Use

(Please do not write below this line – continue on another page if needed)

Concurrence of CDRH, Office of Device Evaluation (ODE)

[Signature]

[Title: Chair, section sign-off]

[Title: Head, section sign-off]

[Title: Member, CDRH]

Page 1 of 1